Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Is Holding On To Its Supply Of AstraZeneca COVID-19 Vaccine

Executive Summary

US is keeping a ‘small inventory’ of AstraZeneca’s vaccine so people in the US can receive it immediately following authorization, White House official says. President Biden seeks to boost vaccine manufacturing in India in parntership with India, Japan, and Australia.

You may also be interested in...



COVID-19 Vaccine Regulatory Strategy Evolving With The Pandemic

AstraZeneca and Novavax have not filed EUAs for their vaccines, and they never might. The pathway remains viable in the short-term, but as BLAs are approved and supplies are no longer short, the window may close.

Real-World Evidence On COVID 19 Vaccines Coming Into US FDA

Peter Marks says agency is getting first RWE readouts of vaccine safety; AstraZeneca’s vaccine has no expiration date, so stockpile is not currently at risk of being thrown out, the CBER director tells a House hearing.

Coronavirus Notebook: AZ Vaccine Suspended In Some European Countries, Janssen’s Vaccine Approved In EU

The European Commission has ordered more doses of the Pfizer/BioNTech vaccine to tackle COVID-19 “hotspots,” and has extended its export authorization scheme by three months. The EU’s procurement strategy has come under fire again, Lilly's antibodies have started a rolling review at the European Medicines Agency, and Sierra Leone has received its first coronavirus vaccines via the COVAX Facility.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS143991

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel